Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:BDRXNASDAQ:CRGXNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.70+0.3%$2.02$1.29▼$7.85$185.97M1.241.79 million shs965,006 shsBDRXBiodexa Pharmaceuticals$1.41+2.2%$1.72$1.14▼$74.00$51.53M1.15586,450 shs30,999 shsCRGXCARGO Therapeutics$4.14+2.1%$4.21$3.00▼$25.45$190.67M0.47519,714 shs338,960 shsPRMEPrime Medicine$1.32-7.0%$1.68$1.12▼$8.27$173.13M1.91.22 million shs2.29 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+2.74%-9.14%+3.68%-52.66%-64.27%BDRXBiodexa Pharmaceuticals+3.76%-5.48%-16.36%-66.91%+137,999,900.00%CRGXCARGO Therapeutics-0.56%-11.23%+0.67%+9.65%-79.96%PRMEPrime Medicine+6.77%-17.92%+9.23%-43.65%-74.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon1.6639 of 5 stars3.51.00.00.01.41.70.6BDRXBiodexa Pharmaceuticals0.1489 of 5 stars0.03.00.00.00.00.00.6CRGXCARGO Therapeutics2.0668 of 5 stars2.90.00.00.02.71.71.3PRMEPrime Medicine2.538 of 5 stars3.60.00.00.00.63.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.671,001.28% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/ACRGXCARGO Therapeutics 1.86Reduce$15.00262.76% UpsidePRMEPrime Medicine 3.13Buy$13.14895.67% UpsideCurrent Analyst Ratings BreakdownLatest BDRX, PRME, CRGX, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/3/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/3/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/28/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ABDRXBiodexa Pharmaceuticals$83K620.81N/AN/A$42.56 per share0.03CRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/APRMEPrime Medicine$2.98M58.04N/AN/A$1.37 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/ACRGXCARGO Therapeutics-$98.15M-$3.72N/AN/AN/AN/A-38.16%-33.94%5/13/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.65N/AN/AN/AN/A-107.87%-74.97%N/ALatest BDRX, PRME, CRGX, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CRGXCARGO Therapeutics-$0.70N/AN/AN/AN/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.45109.55%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18BDRXBiodexa Pharmaceuticals0.022.16N/ACRGXCARGO TherapeuticsN/A18.9418.95PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ABDRXBiodexa Pharmaceuticals17.51%CRGXCARGO Therapeutics93.16%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%BDRXBiodexa Pharmaceuticals0.34%CRGXCARGO Therapeutics1.38%PRMEPrime Medicine23.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableCRGXCARGO Therapeutics11646.11 million45.39 millionN/APRMEPrime Medicine234131.16 million100.38 millionOptionableBDRX, PRME, CRGX, and ANNX HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue EstimatesMay 8 at 10:25 AM | zacks.comPrime Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 8 at 8:00 AM | globenewswire.comT. Rowe Price Investment Management Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)April 30, 2025 | marketbeat.comPrime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359April 26, 2025 | seekingalpha.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 5.43%April 26, 2025 | aaii.comPrime Medicine, Inc. (NYSE:PRME) Shares Bought by Walleye Capital LLCApril 22, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by AnalystsApril 16, 2025 | marketbeat.comPrime Medicine Stock Price, Quotes and ForecastsApril 13, 2025 | benzinga.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 12.42%April 5, 2025 | aaii.comWhy Prime Medicine, Inc.’s (PRME) Stock Is Down 10.30%April 2, 2025 | aaii.comPrime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comPrime and Beam, born of same lab, pursuing rival gene-editing treatmentsMarch 19, 2025 | statnews.comPrime Medicine unveils program for treatment of AATDMarch 18, 2025 | markets.businessinsider.comPrime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy RatingMarch 18, 2025 | tipranks.comPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 18, 2025 | globenewswire.comPrime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy RatingMarch 18, 2025 | tipranks.comJ.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)March 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDRX, PRME, CRGX, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$1.70 +0.01 (+0.30%) Closing price 03:59 PM EasternExtended Trading$1.72 +0.02 (+1.42%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Biodexa Pharmaceuticals NASDAQ:BDRX$1.41 +0.03 (+2.17%) Closing price 03:44 PM EasternExtended Trading$1.41 0.00 (0.00%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.CARGO Therapeutics NASDAQ:CRGX$4.14 +0.09 (+2.10%) Closing price 03:59 PM EasternExtended Trading$4.12 -0.01 (-0.36%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Prime Medicine NYSE:PRME$1.32 -0.10 (-7.04%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.06 (+4.47%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
